Peel Therapeutics begins Phase I solid tumour trial
The trial will assess the safety, tolerability, pharmacokinetics and initial antitumor activity of PEEL-224.

The trial will assess the safety, tolerability, pharmacokinetics and initial antitumor activity of PEEL-224.
The randomised trial will enrol over 3,700 individuals with acute rhinosinusitis.
With the 20th birthday of the renowned Clinical Trial Supply East Coast conference in October, we look at topic changes…
ByUPB-101 was found to hinder production of cytokine from CD4+ T cells and ILC2, in pre-clinical studies.
Tislelizumab’s safety profile was in line with prior trials without any new safety signals observed.
The trial will analyse the safety, tolerability and pharmacokinetics of various doses of OLX-07010 in healthy elderly subjects.
Efficacy and safety of SL-1002 are the primary endpoints of the trial.
All clinics conducting clinical trials using VialConnect have access to the ModMed interface.
Thank you for subscribing to Clinical Trials Arena